Skip to content

In the BioHarmony Drug Report Database

Ziprasidone

Geodon (ziprasidone) is a small molecule pharmaceutical. Ziprasidone was first approved as Geodon on 2001-02-05. It is used to treat schizophrenia, schizophrenia spectrum and other psychotic disorders, and tourette syndrome in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 2A, and D(2) dopamine receptor. In addition, it is known to target sodium-dependent serotonin transporter, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 7, 5-hydroxytryptamine receptor 1D, histamine H1 receptor, and sodium-dependent noradrenaline transporter.
Trade Name Geodon
Common Name Ziprasidone
Indication schizophrenia, schizophrenia spectrum and other psychotic disorders, tourette syndrome
Drug Class Antipsychotic with binding activity on serotonin (5HT2A) and dopamine (D2) receptors
Ziprasidone
Get full access now